Entera Bio (ENTX) Competitors $2.04 0.00 (0.00%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$2.04 0.00 (-0.25%) As of 07/17/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. RCKT, OCGN, GLUE, HRTX, CADL, AVIR, NGNE, TNXP, PVLA, and ABEOShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Rocket Pharmaceuticals (RCKT), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), Heron Therapeutics (HRTX), Candel Therapeutics (CADL), Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Tonix Pharmaceuticals (TNXP), Palvella Therapeutics (PVLA), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors Rocket Pharmaceuticals Ocugen Monte Rosa Therapeutics Heron Therapeutics Candel Therapeutics Atea Pharmaceuticals Neurogene Tonix Pharmaceuticals Palvella Therapeutics Abeona Therapeutics Entera Bio (NASDAQ:ENTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Which has stronger valuation and earnings, ENTX or RCKT? Entera Bio has higher revenue and earnings than Rocket Pharmaceuticals. Entera Bio is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$180K515.10-$9.54M-$0.26-7.85Rocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.27 Does the media favor ENTX or RCKT? In the previous week, Rocket Pharmaceuticals had 45 more articles in the media than Entera Bio. MarketBeat recorded 45 mentions for Rocket Pharmaceuticals and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Rocket Pharmaceuticals' score of 0.17 indicating that Entera Bio is being referred to more favorably in the media. Company Overall Sentiment Entera Bio Very Positive Rocket Pharmaceuticals Neutral Which has more volatility & risk, ENTX or RCKT? Entera Bio has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Is ENTX or RCKT more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Rocket Pharmaceuticals' return on equity of -64.92% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Entera Bio-4,525.11% -95.10% -82.77% Rocket Pharmaceuticals N/A -64.92%-56.13% Do institutionals and insiders hold more shares of ENTX or RCKT? 14.1% of Entera Bio shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 10.4% of Entera Bio shares are held by insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend ENTX or RCKT? Entera Bio presently has a consensus price target of $10.00, suggesting a potential upside of 390.20%. Rocket Pharmaceuticals has a consensus price target of $18.60, suggesting a potential upside of 456.89%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Entera Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41 SummaryRocket Pharmaceuticals beats Entera Bio on 9 of the 15 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.72M$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-7.8520.2928.1019.86Price / Sales515.10302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book8.877.838.265.67Net Income-$9.54M-$55.11M$3.24B$257.80M7 Day Performance17.92%3.21%1.48%1.87%1 Month Performance2.51%12.86%8.07%10.92%1 Year Performance9.09%5.06%30.29%18.51% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio2.9359 of 5 stars$2.04flat$10.00+390.2%+7.9%$92.72M$180K-7.8520Positive NewsRCKTRocket Pharmaceuticals4.8488 of 5 stars$3.05+3.0%$18.60+509.8%-85.8%$325.71MN/A-1.16240Trending NewsGap UpOCGNOcugen1.3955 of 5 stars$1.11-2.6%$6.00+440.5%-45.4%$324.15M$4.05M-5.8480News CoverageGLUEMonte Rosa Therapeutics2.1256 of 5 stars$5.26+1.9%$15.33+191.5%+24.5%$323.54M$159.49M65.7690News CoveragePositive NewsHRTXHeron Therapeutics3.5657 of 5 stars$2.12-2.8%$5.00+135.8%-42.9%$323.44M$148.52M-35.33300CADLCandel Therapeutics2.5172 of 5 stars$6.43+10.7%$22.00+242.1%+5.3%$322.16MN/A-4.8060Positive NewsAVIRAtea Pharmaceuticals2.7633 of 5 stars$3.76+2.5%$6.00+59.6%-10.6%$321.78MN/A-2.2870Positive NewsNGNENeurogene3.4539 of 5 stars$22.26+3.9%$46.17+107.4%-49.0%$317.47M$925K-5.1290Positive NewsTNXPTonix Pharmaceuticals2.5416 of 5 stars$42.78+4.7%$585.00+1,267.5%-20.8%$314.73M$10.04M-0.0250Gap UpPVLAPalvella Therapeutics2.5393 of 5 stars$27.55+4.1%$46.29+68.0%N/A$304.59MN/A-2.28N/APositive NewsABEOAbeona Therapeutics3.7509 of 5 stars$5.92+3.1%$19.25+225.2%+22.3%$302.87M$3.50M-4.6690 Related Companies and Tools Related Companies Rocket Pharmaceuticals Competitors Ocugen Competitors Monte Rosa Therapeutics Competitors Heron Therapeutics Competitors Candel Therapeutics Competitors Atea Pharmaceuticals Competitors Neurogene Competitors Tonix Pharmaceuticals Competitors Palvella Therapeutics Competitors Abeona Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.